Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    Aptevo | Hemophilia B
Previous Study | Return to List | Next Study

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03855280
Recruitment Status : Not yet recruiting
First Posted : February 26, 2019
Last Update Posted : November 5, 2019
Sponsor:
Information provided by (Responsible Party):
Aptevo Therapeutics

Brief Summary:
Phase 3/4, single arm, open-label study to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age.

Condition or disease Intervention/treatment Phase
Hemophilia B Drug: APVO101 Phase 3

Detailed Description:

Study APVO101-903 is a Phase 3/4, single arm, open-label clinical trial. The purpose of the study is to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age. The study is designed to gather information in two age groups of previously treated (with a minimum of 50 previous ED to factor IX replacement therapy) pediatric patients, specifically those < 6 years of age and 6 to <12 years of age.

Study APVO101-903 consists of three distinct phases:

  • PK Phase - PK evaluation will consist of administration of a single 75 ± 5 IU/kg dose, followed by factor IX activity and safety assessments up to 50 hours post-infusion.
  • Treatment Phase - subjects will receive APVO101 prophylaxis (starting prophylaxis dose to be determined based on APVO101 recovery; ideally within the recommended dose range: 35 - 75 IU/kg; twice weekly) for 50 ED (approximately 6 months).
  • Continuation Phase - subjects may continue to receive APVO101 prophylaxis (recommended dose range: 35 - 75 IU/kg; twice weekly) for an additional ≥ 50 ED.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Intervention Model: Single Group Assignment
Intervention Model Description:

Phase 3/4, single arm, open-label study with three defined phases:

  • PK Phase: Initial PK evaluation - single dose of APVO101
  • Treatment Phase: APVO101 prophylaxis treatment for 50 ED
  • Continuation Phase: After completion of the Treatment Phase, subjects may continue APVO101 prophylaxis treatment (for an additional ≥ 50 ED)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Estimated Study Start Date : November 15, 2019
Estimated Primary Completion Date : August 1, 2021
Estimated Study Completion Date : September 1, 2021


Arm Intervention/treatment
Experimental: APVO101 Drug: APVO101
APVO101: 35 - 75 IU/kg; twice weekly
Other Names:
  • IB1001
  • Recombinant factor IX
  • IXINITY




Primary Outcome Measures :
  1. Annualized Bleed Rate [ Time Frame: 6 Months ]
    Measure assessed during the Treatment Phase


Secondary Outcome Measures :
  1. Area under the plasma concentration curve from time 0 to t (AUC0-t) [ Time Frame: Pre-infusion to 50 hours following infusion ]
    Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours

  2. Terminal Half-life (t 1/2) [ Time Frame: Pre-infusion to 50 hours following infusion ]
    Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours

  3. Maximum post-infusion plasma concentration (Cmax) [ Time Frame: Pre-infusion to 50 hours following infusion ]
    Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours

  4. Incremental Recovery [ Time Frame: Pre-infusion to 50 hours following infusion ]
    Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours

  5. Clearance (CL) [ Time Frame: Pre-infusion to 50 hours following infusion ]
    Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours

  6. Volume of Distribution at steady-state (V dss) [ Time Frame: Pre-infusion to 50 hours following infusion ]
    Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours

  7. Degree of Hemorrhage Control [ Time Frame: 6 Months ]

    Subjects rating of bleed control within 6 hours of the time bleeding has stopped:

    Excellent: a dramatic response with abrupt pain relief and clear reduction in joint or hemorrhage site size; Good: pain relief or reduction in hemorrhage site size that may have required an additional infusion for resolution; Fair: probable or slight beneficial response usually requiring one of more additional infusions for resolution; Poor: no improvement or condition worsens.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: < 11.5 years of age at the time of the first dose and < 12 years throughout the Treatment Phase of the study (for at least 50 ED).
  2. Informed consent: subject's parent or legal guardian written Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent. An assent form (IRB/EC-approved) will be obtained, when required by local regulations/guidelines.
  3. Willingness and ability to make the required study visits, and follow instructions while enrolled in the study (for at least 50 ED; approximately 6 months).
  4. Documented severe or moderately severe hemophilia B diagnosis (factor IX activity ≤ 2 IU/dL); in addition, severity may be indicated by the occurrence of one or more joint bleeding episode(s) at any point in the child's medical history requiring infusion(s) to replace factor IX.
  5. Subjects must be on prophylaxis or switch to a prophylaxis regimen for the duration of the study.
  6. Previously treated patients with a minimum of 50 ED (as documented and determined by the investigator) to a preparation/blood components containing factor IX.
  7. Willingness to adhere to the 4-day washout period of any factor IX replacement therapy prior to PK evaluation. In case of previous exposure to a factor IX product with a prolonged half-life, a washout period of 3 half-lives is required in order to achieve steady state factor IX level prior to exposure to APVO101.
  8. Immunocompetent (CD4 count > 400/mm3) and not receiving immune modulating or chemotherapeutic agents.
  9. Platelet count at least 150,000/mm3.
  10. Liver function: alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2 times the upper limit of the normal range.
  11. Total bilirubin ≤ 1.5 times the upper limit of the normal range.
  12. Renal function: serum creatinine ≤ 1.25 times the upper limit of the normal range.
  13. Hemoglobin ≥ 7 g/dL.

Exclusion Criteria:

  1. History of factor IX inhibitor ≥ 0.6 Bethesda Units (BU).
  2. Existence of another coagulation disorder.
  3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular coagulation (DIC).
  4. Use of an investigational drug within 30 days prior to study entry.
  5. Previous use of APVO101.
  6. Use of medications that could impact hemostasis, such as aspirin.
  7. Known hypersensitivity to the active substance or to any of the excipients in the investigational products.
  8. Known allergic reaction to hamster proteins.
  9. History of poor compliance, geographic isolation, unreliable transportation, a serious medical or social condition, or any other circumstance that, in the opinion of the investigator, would interfere with participation or compliance with the study protocol.
  10. History of adverse reaction to either plasma-derived factor IX or recombinant factor IX that interfered with the subject's ability to treat bleeding episodes with a factor IX product.
  11. History of any medical condition that would impact the efficacy evaluation and/or safety evaluation of the study product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03855280


Contacts
Layout table for location contacts
Contact: David Schaaf, MD 206-859-6655 schaafd@apvo.com
Contact: Julissa Leon 206-838-0513 leonj@apvo.com

Locations
Layout table for location information
Colombia
Hospital Pablo Tobon Uribe Not yet recruiting
Medellín, Antioquia, Colombia, 050034
Sponsors and Collaborators
Aptevo Therapeutics
Investigators
Layout table for investigator information
Study Chair: David Schaaf, MD Aptevo Therapeutics

Layout table for additonal information
Responsible Party: Aptevo Therapeutics
ClinicalTrials.gov Identifier: NCT03855280     History of Changes
Other Study ID Numbers: APVO101-903
First Posted: February 26, 2019    Key Record Dates
Last Update Posted: November 5, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked